"The earlier the better", evolution of Pulmonary Function Tests (PFT) in severe asthma patients treated with Benralizumab after two years.

<bold>Introduction:</bold> Since the appearance of biological treatments, the management of severe asthma (SA) has changed. Not only have clinical outcomes improved, but also PFT. <bold>Aim:</bold> The aim is to analyse the relationship between PFT improvement and years of evolution (YEA) of asthma. <bold>Methods:</bold> Retrospective study carried out in patients from our SA Unit treated with Benralizumab with a 2-year follow-up. They underwent clinical, analytical and PFT control annually. <bold>Results:</bold> 50 patients were included. 54% female, mean age 61.6 ± 11.5, YEA 19.3 ±11.7, median eosinophil count 710/mm3 ±353. Regarding PFT after two years there is a global improvement in FEV1 2123(±758ml) to 2612(±810ml), FVC 3193(±957ml) to 3524(±965ml). Differences were statistically significant from baseline to first and second year but not between these last two. These results are also obtained when analysing PFT by percentage. In a subgroup analysis depending on YEA (<15y n=21/>15y n=29) we observed grater improvement in <15y: FEV1 514 (±458ml) vs 474 (±580ml), FVC 561 (±458ml) vs 483 (±476ml) only in the first group differences were statistically significant annually (Figure 1). <fig><object-id>erj;64/suppl_68/PA4767/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Conclusions:</bold> Treatment with Benralizumab in SA has shown to improve PFT. Early diagnosis and close follow-up are crucial as patients with shorter evolution have better PFT improvements, and also a sustained gain in the follow-up.